Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7386 in Advanced Solid Tumors and Colorectal Cancer
NCT03833700Phase 1Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of e7386 in Solid neoplasm, colorectal neoplasm, gastrointestinal tumor and 5 more (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting Toxicities at 28 days and Adverse Events and Serious Adverse Events at 6 years. Started Mar 2019; status: active, not recruiting.
02
Drugs
e7386
03
Conditions
Solid neoplasmcolorectal neoplasmgastrointestinal tumordesmoid tumorpancreatic neoplasm
Beyond the preview
Go deeper on NCT03833700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833700.